IFI27L1: A Potential Drug Target and Biomarker (G122509)

Target Name: IFI27L1

NCBI ID: G122509

IFI27L1

IFI27L1: A Potential Drug Target and Biomarker

Interferon alpha-inducible protein 27-like protein 1 (IFI27L1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. IFI27L1 is a cytoplasmic protein that is expressed in most tissues and cells, and its functions include regulating cell growth, differentiation, and survival. In this article, we will explore the potential implications of IFI27L1 as a drug target and biomarker.

Potential Drug Target

IFI27L1 has been shown to play a critical role in the regulation of cell growth and differentiation, and its dysfunction has been implicated in the development of various diseases. One of the most promising aspects of IFI27L1 is its potential as a drug target. IFI27L1 has been shown to interact with various signaling pathways, including the PI3K/Akt signaling pathway, which is known to play a crucial role in cancer progression and the development of neurodegenerative diseases.

IFI27L1 has also been shown to interact with the TGF-β signaling pathway, which is involved in the regulation of cell growth, differentiation, and survival. The TGF-β signaling pathway is known to be involved in the development of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Therefore, IFI27L1 may be a promising drug target for these diseases.

Biomarker

IFI27L1 has also been shown to be a potential biomarker for various diseases. IFI27L1 has been shown to be involved in the regulation of cell growth and differentiation, which may be involved in the development of various diseases. For example, IFI27L1 has been shown to play a role in the regulation of cancer cell growth and has been shown to be involved in the development of various types of cancer.

IFI27L1 has also been shown to be involved in the regulation of autoimmune disorders, including the regulation of T cell development and function. IFI27L1 has been shown to play a role in the regulation of T cell development and has been shown to be involved in the development of autoimmune disorders. Therefore, IFI27L1 may be a potential biomarker for autoimmune disorders.

Conclusion

In conclusion, IFI27L1 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. IFI27L1 has been shown to play a critical role in the regulation of cell growth and differentiation, and its dysfunction has been implicated in the development of various diseases. Therefore, IFI27L1 may be a promising drug target and biomarker for these diseases. Further research is needed to fully understand the role of IFI27L1 as a drug target and biomarker.

Protein Name: Interferon Alpha Inducible Protein 27 Like 1

Functions: Plays a role in the apoptotic process and has a pro-apoptotic activity

The "IFI27L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFI27L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets